Skip to main content

Global Cell and Gene Therapy Market Achieves 23% CAGR, Enhancing Healthcare Access 2030

 


The global cell and gene therapy market is experiencing significant expansion, driven by rising approvals and advancements in treatment modalities. The market is projected to grow at a compound annual growth rate of ~23% over the forecast period. This rapid growth is fueled by increasing investments in biopharmaceutical R&D, favorable regulatory support, and expanding clinical applications of gene-modified and cell-based treatments. 

Cell and gene therapy represent two transformative approaches in modern medicine to treat or potentially cure diseases at their root cause. Cell therapy involves the transplantation or modifying living cells to restore or enhance their function, often used for regenerative medicine and immunotherapy applications. Gene therapy, on the other hand, focuses on modifying or replacing faulty genes to correct genetic disorders, cancers, and other chronic conditions. These therapies hold immense promise for conditions previously considered untreatable, driving extensive research and commercial interest.

To request a free sample copy of this report, please visit below
https://meditechinsights.com/cell-and-gene-therapy-market/request-sample/

The expanding applications of CAR-T cell therapy to drive market growth

CAR-T (Chimeric Antigen Receptor T-cell) therapy is revolutionizing the treatment of hematologic cancers, significantly boosting the demand for cell and gene therapies. This therapy involves modifying a patient’s T cells to express a receptor specific to cancer cells, allowing for precise and potent immune responses. The dramatic success of CAR-T therapies in treating relapsed or refractory leukemias and lymphomas have fueled their rapid adoption. Regulatory agencies have granted approvals for multiple CAR-T therapies, and ongoing clinical trials are expanding applications into solid tumours and autoimmune disorders. Additionally, advancements in allogeneic (off-the-shelf) CAR-T therapies aim to overcome existing challenges related to patient-specific manufacturing. As CAR-T therapies' efficacy and safety profiles improve, they are expected to play a central role in the broader adoption of cell and gene therapies, enhancing patient outcomes and market growth.

Next-generation gene editing technologies enhancing precision and accessibility

Innovations in gene editing, particularly CRISPR-Cas9 and base editing, are revolutionizing the field of gene therapy by enabling highly precise genetic modifications. CRISPR technology allows targeted corrections of faulty genes with minimal off-target effects, significantly improving treatment safety and effectiveness. Furthermore, newer gene-editing platforms, such as prime editing, offer enhanced control over genetic alterations, expanding therapeutic possibilities for rare genetic disorders and cancers. The integration of artificial intelligence (AI) in gene editing is also accelerating the discovery of novel therapeutic targets and improving editing efficiency. Additionally, advancements in non-viral delivery methods, such as lipid nanoparticles, are making gene therapy more scalable and accessible. As these technologies continue to evolve, they are expected to drive a new wave of gene-based therapies, improving affordability, regulatory acceptance, and widespread clinical adoption across diverse therapeutic areas.

 Competitive Landscape Analysis

The global cell and gene therapy market is marked by the presence of established and emerging market players such as Sartorius AG; Novartis AG; Thermo Fisher Scientific, Inc.; Merck KGaA; Charles River Laboratories; Cell and Gene Therapy Catapult; Lonza; WuXi AppTec; Takara Bio Inc.; Bristol Myers Squibb; FUJIFILM Holdings Corporation; and F. Hoffmann-La Roche Ltd. among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

🔗 Want deeper insights? Download the sample report here:
https://meditechinsights.com/cell-and-gene-therapy-market/request-sample/

Global Cell and Gene Therapy Market Segmentation

This report by Medi-Tech Insights provides the size of the global cell and gene therapy market at the regional- and country-level from 2023 to 2030. The report further segments the market based on therapy type, indication, and end-user.

Market Size & Forecast (2023-2030), By Therapy Type, USD Million

  • Cell Therapy
  • Gene Therapy

Market Size & Forecast (2023-2030), By Indication, USD Million

  • Oncology
  • Autoimmune Diseases
  • Neurological Diseases
  • Cardiovascular Diseases
  • Others

Market Size & Forecast (2023-2030), By End-user, USD Million

  • Hospitals & Speciality Clinics
  • Pharma & Biotech Companies
  • Academic Research Institutes
  • Others

Market Size & Forecast (2023-2030), By Region, USD Million

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
 Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com 

Comments

Post a Comment

Popular posts from this blog

Global Biotechnology Market to grow at 13–15% CAGR as CRISPR use expands globally by 2029

  The global biotechnology market is set to witness a growth rate of 13-15% in the next 5 years.  Advancements in genetic engineering and genomics; growing demand for biopharmaceuticals; rising incidence of chronic diseases; growth in environmental and agricultural biotechnology; increased investment in R&D; growing demand for synthetic biology; and presence of favorable government initiatives are some of the key factors driving the biotechnology market. Biotechnology is the scientific field that uses biological organisms, systems, or processes to develop products and technologies aimed at improving health, agriculture, environmental sustainability, and industrial efficiency. By applying principles of genetics, molecular biology, and biochemistry, biotechnology enables advancements like genetic engineering, biopharmaceutical development, biofuels, and genetically modified organisms (GMOs). This field is instrumental in producing therapies for diseases, increasing crop r...
Post a Comment
Read more

Global Multi Cancer Early Detection Market expanding 15–20% CAGR through personalized care 2030

  The multi cancer early detection market is expected to grow at a CAGR of around 15-20% during the forecast period.  This growth is primarily due to the rising awareness and increasing demand for early-stage screening tools, especially as cancer rates continue to rise globally, and technological advancements in screening methods. However, high costs and strict regulations can still hinder the market growth.  Multi Cancer Early Detection (MCED) refers to tests designed to detect multiple cancers, often from a single blood sample, unlike traditional methods, which can include multiple diagnostic tests or biopsies. These tests look for signs like DNA methylation patterns or small traces of tumor DNA floating in the bloodstream. The primary goal is early cancer detection, ideally before any symptoms appear, so the overall treatment is more effective and less expensive. Download a free sample report now 👉 https://meditechinsights.com/multi-cancer-early-detection-marke...
Post a Comment
Read more

Global Structural Heart Devices Market growth 9% CAGR with favorable reimbursement scenarios 2030

  The global structural heart devices market is set to witness a CAGR of ~9% in the next 5 years.  The rising geriatric population & corresponding rise in the prevalence of heart disease, technological advancements in structural heart devices, regulatory approval for expanded indications for several transcatheter heart valves, and increasing awareness and favorable reimbursements for these procedures in key markets are some of the pivotal factors driving the growth of the structural heart devices market. However, high device costs, complex procedures, and stringent regulatory hurdles continue to restrain market uptake.  Structural heart disease occurs when something is wrong with one’s heart valves, walls, chambers or muscles. It exists from birth or develops as one age. It includes conditions such as congenital heart disease, cardiomyopathy, and heart valve disease. Heart valve devices, occluders & delivery systems, annuloplasty rings, heart access systems, cl...
Post a Comment
Read more